Search Results

Total 941 documents found.

•  

• About Takeda Overview
• Takeda is a research-based global pharmaceutical company. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

• Basic Purchasing Policy
• In order to develop superior pharmaceutical products and contribute to the business progression of the Company, the General Purchasing Department buyers and staff shall obtain the best and most economical materials from global purchasing markets in a stable manner; competing with the purchasing staff of other global pharmaceutical companies.

• Takeda Pharmaceutical Company Limited
• Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan, and one of the global leaders of the industry. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products.

• Takeda Announces Appointment of New Corporate Officers June 25, 2010
• Osaka, Japan, June 25, 2010 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced the appointment of new corporate officers which was resolved today at the extraordinary Board of Directors’ Meeting, and the details of the appointment are as follows:

• Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity November 2, 2009
• San Diego, CA – November 1, 2009 and Osaka, Japan – November 2, 2009 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

• Takeda to Create Global Centers of Excellence
  Reorganization helps Takeda realize globalization vision March 31, 2009
• Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.

• Takeda Establishes Presence in Canada
  Company to be based in Mississauga, Ontario March 27, 2009
• Deerfield, III. (March 26, 2009) and Osaka, Japan (March 27, 2009) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced the establishment of Takeda Canada Inc., expanding the company’s North American presence into the world’s eighth largest pharmaceutical market. Takeda Canada will be headquartered in Mississauga, Ontario, west of Toronto, one of the top three biotech areas in North America.

• Takeda Pharmaceuticals and TAP Pharmaceutical Products Inc. Merge
  Combined Company is a Top 15 Pharmaceutical Company in the United States July 2, 2008
• Osaka, Japan and Deerfield, Ill. – July 1, 2008 (US Time) – Takeda Pharmaceutical Company Limited today announced that Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. merged with TAP Pharmaceutical Products Inc. (TAP), forming one of the top 15 pharmaceutical companies in the United States.

• Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics May 27, 2008
• CAMBRIDGE, Mass., USA and OSAKA, Japan, May 27, 2008 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional therapeutic areas. This landmark alliance is the first major RNAi therapeutics partnership between a Japanese pharmaceutical company and a U.S. biotechnology company, representing a new frontier in the advancement of RNAi therapeutics to patients on a global basis.

• Abbott, Takeda Conclude TAP Joint Venture May 1, 2008
• OSAKA, Japan, and ABBOTT PARK, Ill., May 1, 2008 – Abbott and Takeda Pharmaceutical Company Limited have concluded their TAP Pharmaceutical Products Inc. (TAP) joint venture.

• Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
  Companies to Evenly Divide Value of TAP March 20, 2008
• OSAKA, Japan, and ABBOTT PARK, Ill., March 19, 2008(US Time) – Takeda Pharmaceutical Company Limited and Abbott have entered into an agreement to conclude their TAP Pharmaceutical Products Inc. (TAP) joint venture. The companies expect the transaction to close within 30-60 days.

• TAP Pharmaceutical Products Inc. Filed New Drug Application for TAK-390MR in Patients with Acid-Related Disorders January 4, 2008
• Osaka, Japan, January 4, 2008 --- Takeda Pharmaceutical Company Limited (Takeda) announced today that TAP Pharmaceutical Products Inc. (TAP), a 50-50 joint venture with Abbott Laboratories, had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for TAK-390MR.

• Takeda to Transfer its Business of Leasing of Office Building to the Consolidated Subsidiary by Corporate Demerger April 26, 2007
• OSAKA, JAPAN, April 26, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly owned subsidiary, Takeda Pharmaceutical Real Estate Company Ltd. ("Takeda Estate") approved at their respective Board of Directors' Meetings the demerger transferring Takeda's business of leasing of office building to Takeda Estate.

• Takeda's New Structure for Pharmaceutical Marketing Division in Japan March 20, 2007
• Osaka, Japan, March 20, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") announced today a reorganization of its Pharmaceutical Marketing Division responsible for domestic ethical drug business effective April 1, 2007, that is a shift from current 156 representative offices under 13 branches to 19 regional groups and 74 representative offices under 12 branches.

• Merger of Three Consolidated Subsidiaries, Daiwa Estate, Shinwa Estate and Takeda Pharmaceutical Real Estate January 31, 2007
• OSAKA, JAPAN, January 31, 2007 --- Takeda Pharmaceutical Company Limited ("Takeda") announced that its Board of Directors resolved today the merger of three wholly owned subsidiaries which are; Daiwa Estate Company, Ltd. ("Daiwa"), Shinwa EstateCompany, Ltd. ("Shinwa") and Takeda Pharmaceutical Real Estate Company, Ltd. ("Takeda Estate") as follows:

• Termination of License Agreement for Tavocept™ in Japan November 2, 2006
• Tokyo/Osaka, Japan, November 2, 2006 --- ASKA Pharmaceutical Co., Ltd. ("ASKA", Tokyo, Japan) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) announced the termination of the License Agreement of March 15, 2006 that had previously been entered into by Takeda, ASKA, KI Pharmaceuticals, Inc.(*) ("KI Pharma", Tokyo, Japan) and BioNumerik Pharmaceuticals, Inc. (San Antonio, Texas, "BioNumerik") with respect to the investigational new drug known as Tavocept™ for the territory of Japan. Tavocept™ (generic name: dimesna) is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik.

• AMITIZA™(lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States
  Novel mechanism of action provides effective and predictable relieffor adults living with chronic idiopathic constipation April 26, 2006
• Bethesda, Md., and Lincolnshire, Il., April 25, 2006- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc., announced today that AMITIZA™ (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administ-ration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. AMITIZA (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently."AMITIZA is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners," said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo. "As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuti-cals North America to make this innovative new therapeutic option available to physicians and patients in the United States."AMITIZA works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. In clinical trials, 60 percent of patients who used AMITIZA experienced a spontaneous bowel movement within the first 24 hours. AMITIZA improved signs and symptoms related to chronic constipation, including abdominal bloating, discomfort, stool consistency and straining. Additionally, these symptomatic improvements lasted over the six to 12 month treatment period. "The availability of AMITIZA™ is exciting news for the millions of Americans who suffer from chronic idiopathic constipation and deal with its daily conse-quences," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine. "Unlike many treatments that may fail to control symptoms adequately or lose effectiveness with time, AMITIZA provides fast and predictable relief of chronic idiopathic constipation."AMITIZA is developed by Sucampo Pharmaceuticals, Inc., and will be jointly marketed in the United States by Sucampo Pharmaceuticals, Inc., and Takeda Pharma-ceuticals North America, Inc. The AMITIZA sales force in the United States will comprise representatives from both companies."Takeda looks forward to working with Sucampo to successfully launch AMITIZA and help make it a trusted and valuable therapy for the treatment of chronic idiopathic constipation," said Art Rice, general manager, Gastroenterology. "AMITIZA has been shown to deliver targeted and predictable relief to people with chronic idiopathic constipation, and we believe that through its novel mechanism of action, this drug may help fill an important therapeutic gap for many patients."

• License Agreement for Tavocept™ in Japan March 16, 2006
• Tokyo/Osaka, Japan, March 16, 2006 --- ASKA Pharmaceutical Co., Ltd. ("ASKA", Tokyo, Japan) and Takeda Pharmaceutical Company Limited ("Takeda", Osaka, Japan) announced today that both parties, KI Pharmaceuticals, Inc.(*) ("KI Pharma", Tokyo, Japan) and BioNumerik Pharmaceuticals, Inc. (San Antonio, Texas, "BioNumerik") have entered into a license agreement for Tavocept™(generic name: dimesna) in Japan.Tavocept™ is a chemoprotective agent originated and developed by BioNumerik.

• Takeda and Pronova Biocare to Agree an License and Supply Agreement on Omacor®, Treatment for Hypertriglyceridemia November 2, 2005
• November 2, 2005, Osaka, Japan and Oslo, Norway −−− Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Pronova Biocare AS (Oslo, Norway, "Pronova") today announced that both parties have entered into a License− and Supply Agreement for Omacor® (generic name: omega−3 acid ethyl esters 90), a pharmaceutical product for the treatment of hypertriglyceridemia.

• Takeda to Disclose Information on Clinical Trials in the Web site July 4, 2005
• Osaka, Japan, July 4, 2005 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced to start disclosure of its clinical trials information in the web-site starting July 1, 2005. This new movement was to follow the joint positioning statement dated January 6 this year by the bodies collectively representing the pharmaceutical industry worldwide such as IFPMA, EFPIA, JPMA and PhRMA. (*)

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next